LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Epigenetic Regulation of Cancer in Response to Chemotherapy
- 1st Edition, Volume 158 - March 27, 2023
- Editors: Joseph Landry, Swadesh Das, Paul B. Fisher
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 9 4 1 8 - 4
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 9 4 1 9 - 1
Epigenetic Regulation of Cancer in Response to Chemotherapy, Volume 158 of the Advances in Cancer Research series, highlights new advances in the field, with this new volume prese… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteEpigenetic Regulation of Cancer in Response to Chemotherapy, Volume 158 of the Advances in Cancer Research series, highlights new advances in the field, with this new volume presenting chapters on timely topics, including Epigenetically Programmed Resistance to Chemotherapy and Promotion of Immune Evasion in Cancer, A Role for the Epigenome in Cancer Cell Drug Tolerance, Histone Methylation and X Chromosomal Genes in Metastasis of Breast Cancer, Targeting Epigenetic Regulation Using Small Molecule Inhibitors, Histone Deacetylase Inhibitors as Sanguine Epigenetic Therapeutics against Pugnacious Lung Cancer, From ecology to oncology: To understand cancer stem cell dormancy, ask a Brine shrimp (Artemia), and more.
Additional chapters cover Predictive Models of Chemoresistance Generated by Crunching the Public Drug Screen, Epigenomic and Genomic Profiling Datasets via Regression-, Machine Learning, and Knowledge-Based Methods, Probing on the Mechanisms of lncRNAs on Cancer Drug Resistance, Drug Tolerant Persister Cells in Cancer: Current Knowledge and Therapeutic Perspectives, and much more.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in the Advances in Cancer Research series
- Includes the latest information on the Epigenetic Regulation of Cancer in Response to Chemotherapy
Researchers and students
1. Epigenetically Programmed Resistance to Chemotherapy and Promotion of Immune Evasion in CancerKatherine Chiappinelli2. A Role for the Epigenome in Cancer Cell Drug ToleranceMarie Classon3. Histone Methylation and X Chromosomal Genes in Metastasis of Breast CancerFei Chen4. Targeting Epigenetic Regulation Using Small Molecule InhibitorsPaul B. Fisher5. Histone Deacetylase Inhibitors as Sanguine Epigenetic Therapeutics against Pugnacious Lung CancerShabir Ahmad Ganai6. From ecology to oncology: To understand cancer stem cell dormancy, ask a Brine shrimp (Artemia)Wei-Jun Yang and Chris Wood7. Predictive Models of Chemoresistance Generated by Crunching the Public Drug Screen, Epigenomic and Genomic Profiling Datasets via Regression-, Machine Learning-, and Knowledge-Based MethodsManny Bacolod8. Probing on the Mechanisms of lncRNAs on Cancer Drug ResistanceChandrima Das9. Drug Tolerant Persister Cells in Cancer: Current Knowledge and Therapeutic PerspectivesXia Weiwei10. Epigenetic Adaptations in Drug-Tolerant Tumor CellsShibasish Chowdhury11. A Role for Epigenetics in the Recovery from Chemotherapy ExposureJoseph Landry12. Reprogramming the Cancer Epigenome - Synergistic Therapy with Epigenetic DrugsVijayalakshmi Mahadevan13. Targeting the Super Elongation Complex for Oncogenic Transcription Driven Tumor Malignancies: Progress in Structure, Mechanisms and Small Molecular Inhibitor DiscoveryKehao Zhao
- No. of pages: 438
- Language: English
- Edition: 1
- Volume: 158
- Published: March 27, 2023
- Imprint: Academic Press
- Hardback ISBN: 9780443194184
- eBook ISBN: 9780443194191
JL
Joseph Landry
Joseph Landry works at Institute of Molecular Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Affiliations and expertise
Institute of Molecular Medicine, Virginia Commonwealth University, VA, USASD
Swadesh Das
Dr. Swadesh Das works at Massey Cancer Center, Richmond, Virginia, USA.
Affiliations and expertise
Massey Cancer Center, Richmond, VA, USAPF
Paul B. Fisher
Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
Affiliations and expertise
Department of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, USARead Epigenetic Regulation of Cancer in Response to Chemotherapy on ScienceDirect